New Milestone for Device that Can 'Smell' Prostate Cancer

A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.

'The use of a gas chromatography (GC)-sensor system combined with advanced statistical methods towards the diagnosis of urological malignancies', published today in the Journal of Breath Research, describes a diagnostic test using a special tool to 'smell' the cancer in men's urine.

Working in collaboration with the University of the West of England's (UWE Bristol) Urological Institute team at Southmead Hospital and Bristol Royal Infirmary, the pilot study included 155 men presenting to urology clinics. Of this group, 58 were diagnosed with prostate cancer, 24 with bladder cancer and 73 with haematuria or poor stream without cancer. The results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.

Urgent need for earlier diagnosis
Professor Chris Probert from the University of Liverpool's Institute of Translational Medicine began work on this project with UWE Bristol when he was working in Bristol as a gastroenterologist with clinical and research interest in inflammatory bowel disease.

The research team used a gas chromatography sensor system called Odoreader that was developed by a team led by Professor Probert and Professor Norman Ratcliffe at UWE Bristol. The test involves inserting urine samples into the Odoreader that are then measured using algorithms developed by the research team at the University of Liverpool and UWE Bristol.

Professor Probert said: "There is an urgent need to identify these cancers at an earlier stage when they are more treatable as the earlier a person is diagnosed the better. After further sample testing the next step is to take this technology and put it into a user friendly format. With help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results."

Like an electronic nose
Professor Norman Ratcliffe said, "There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases. Our aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine. A few years ago we did similar work to detect bladder cancer following a discovery that dogs could sniff out cancer. We have been using the Odoreader, which is like an electronic nose to sense the cancer."

"The Odoreader has a 30 metre column that enables the compounds in the urine to travel through at different rates thus breaking the sample into a readable format. This is then translated into an algorithm enabling detection of cancer by reading the patterns presented. The positioning of the prostate gland which is very close to the bladder gives the urine profile a different algorithm if the man has cancer."

Mr Raj Prasad, Consultant Urologist at Southmead Hospital, North Bristol NHS Trust, said: "If this test succeeds at full medical trial it will revolutionise diagnostics. Even with detailed template biopsies there is a risk that we may fail to detect prostate cancer in some cases. Currently indicators such as diagnosed prostatomegaly (enlarged prostate) and unusually high PSA levels can lead to recommendations for biopsy if there is a concern that cancer may be prevalent. An accurate urine test would mean that many men who currently undergo prostate biopsy may not need to do so."

The pilot trial was funded by the Rotary Club in Bristol who held annual Run for the Future events in Bristol.

The research team is now looking to fund a full clinical trial.

Most Popular Now

Patient Care can Improve with Technology…

A significant part of the American Reinvestment and Recovery Act was the $25 billion invested in health information technology (IT) to improve quality, safety, efficiency in health care while also...

Read more

Medelinked Now Integrated with Microsoft…

Medelinked is now integrated with Microsoft Health and Band. The integration ensures that wellness summary data from Microsoft Health app and Band wearable is available in Medelinked to help users...

Read more

UK Health Show 2016 Partners with Highla…

GovNet Exhibitions has appointed Highland Marketing as its official partner to manage communications for the newly launched UK Health Show 2016. The show will bring together over 4,000 senior healthcare...

Read more

Seniors Embrace Social Technology

Contrary to popular belief, older adults enjoy emailing, instant messaging, Facebook and other forms of social technology. Not only that, but such online networking appears to reduce seniors' loneliness and...

Read more

Leading Digital Health Alliances Announc…

21 - 22 November 2016, Barcelona, Spain. The European Connected Health Alliance (ECHAlliance) and Personal Connected Health Alliance (PCHA) have signed a pivotal agreement to deliver key programme elements for the...

Read more

Big Data Europe Addresses Societal Chall…

Across society, from health to agriculture and transport, from energy to climate change and security, practitioners in every discipline recognise the potential of the enormous amounts of data being created...

Read more

Do Pokémon Go and augmented reality game…

The combination of augmented reality technology, geocaching, and other novel techniques to create innovative active video games (AVGs) has potential personal and public health implications, as discussed in the Editorial...

Read more

Nervecentre Launch Mobile Clinical Photo…

Nervecentre Software has launched a mobile clinical photography solution for nurses and doctors in hospitals. Fully integrated directly into the patient record, the mobile software is completely secure, compliant with...

Read more

in silico Clinical Trials: How Computer …

The term 'in silico clinical trials' refers to: "The use of individualised computer simulation in the development or regulatory evaluation of a medicinal product, medical device, or medical intervention...

Read more

Novartis Convenes Experts to Discuss New…

Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology...

Read more

10th European Medical Information and Co…

29 - 30 November 2016, Berlin, Germany The 10th year of the Annual European Medical Information and Communications Conference is a unique meeting organised by medical information professionals for medical information...

Read more

Pfizer Launches New "Moodivator…

Pfizer Inc. (NYSE:PFE) has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined